



## **BULLETIN**

### **What Massachusetts COVID-19 Vaccine Providers Need to Know Week of 2/1/2023**

#### **LATEST NUMBERS**

- As of 2/1/2023 **5,624,009** people in Massachusetts have been fully vaccinated.

#### **LATEST NEWS**

##### **Evusheld no longer authorized for use in the United States**

As of January 26, 2023, tixagevimab/cilgavimab (EVUSHELD), a combination of two monoclonal antibodies, is [not currently authorized](#) for use in the United States. EVUSHELD was previously recommended for pre-exposure prophylaxis to supplement vaccine protection; however, SARS-CoV-2 variants currently circulating in the United States are [resistant to EVUSHELD™](#).

##### **Ancillary Supply Kit Equipment and Expiration Dates**

The COVID-19 vaccine ancillary kit contents do NOT all expire on the same date. Do not discard the entire kit based on the date printed on the label as it does not apply to all the contents of the kit.

- The expiration date for masks and face shields is indicated on the ancillary supply kit label.
- The expiration date for other supplies (needles, syringes, alcohol prep pads, etc.) are printed on the individual packaging. The expiration date printed on the kit's label does NOT apply to supplies with an expiration date printed on the packaging.

Reminder: Check the expiration date BEFORE using any medical equipment. NEVER USE EXPIRED EQUIPMENT. Always discard expired items.

#### **WHO TO VACCINATE**

COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months.

People can stay [up to date](#) with COVID-19 vaccination by completing a primary series and receiving the most recent booster dose recommended for them by CDC (see [Table 2](#) and [Table 3](#)).

See Appendices B ([People who received COVID-19 vaccine outside the United States](#)) and C ([People who received COVID-19 vaccine as part of a clinical trial](#)) for recommendations for these populations.

## Primary series vaccination

For primary series vaccination, **three monovalent COVID-19 vaccines** (listed in alphabetical order by manufacturer), are recommended: Moderna, Novavax, and Pfizer-BioNTech.

People ages 6 months and older are recommended to complete a primary series.

Monovalent vaccines should be used for the primary series, with one **EXCEPTION**: Children ages 6 months through 4 years who received 2 doses of a monovalent Pfizer vaccine should receive a bivalent Pfizer vaccine as their third primary series dose.

Vaccine products made by the same manufacturer should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](#)).

## Booster vaccination

Monovalent mRNA vaccines are not authorized as a booster dose.

People ages 6 months and older are recommended to receive 1 bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized primary series or previously received monovalent booster dose(s) with one **EXCEPTION**: children 6 months through 4 years who receive a 3-dose Pfizer primary series are not authorized to receive a booster dose at this time regardless of which Pfizer vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in **limited situations** in people ages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.


## Bivalent booster product varies by age

- Ages **6 months-4 years** and completed the **Moderna primary series**: 1 **bivalent Moderna booster** dose.
- Ages **6 months-4 years** and completed **Pfizer primary series**: **No booster** dose is recommended at this time.
- Age **5 years** and completed **Moderna primary series**: **1 bivalent mRNA booster dose (Moderna or Pfizer)**.
- Age **5 years** and completed **Pfizer primary series**: **1 bivalent Pfizer booster** dose. (Regardless of whether the third primary series dose was a monovalent or bivalent Pfizer vaccine)
- Ages **6 years and older** and **any primary series**: **1 bivalent mRNA booster dose (Moderna or Pfizer)**.

## Moderna bivalent COVID-19 vaccine for children 6 months through 5 years of age

- Dark pink capped vial with yellow-bordered label
- Supplied in a **2-dose vial. These are NOT single-dose vials.**
- **This could cause confusion for vaccine administrators as no other vaccine is supplied in a 2-dose vial.**
- The dosage/injection volume for each booster dose is 0.2 mL.

The vial and label for Moderna COVID-19 Vaccine, Bivalent for use in individuals 6 months through 5 years of age are shown in the figure below.



## VACCINE ADMINISTRATION RECOMMENDATIONS

### Four COVID-19 vaccines are currently approved under a BLA or authorized under an EUA by the FDA:

The following COVID-19 vaccines, categorized into three [vaccine types](#), are currently approved under a BLA or authorized under an EUA by the FDA:

- [mRNA vaccines](#)
  - Moderna COVID-19 Vaccine/SPIKEVAX and Moderna COVID-19 Vaccine, Bivalent
  - Pfizer-BioNTech COVID-19 Vaccine/COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- [Protein subunit vaccine](#)
  - Novavax COVID-19 Vaccine, Adjuvanted
- [Adenovirus vector vaccine](#)
  - Janssen (Johnson & Johnson) COVID-19 Vaccine

COVID-19 vaccine products are formulated as follows:

- Monovalent vaccine: The vaccine product is based on the original (ancestral) strain of SARS-CoV-2
- Bivalent vaccine: The vaccine product is based on the original (ancestral) strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 (BA.4/BA.5) variants of SARS-CoV-2

None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines.

Janssen COVID-19 Vaccine is authorized for adults ages 18 years and older in [certain limited situations](#) due to safety considerations (see [Appendix A](#)).

COVID-19 vaccine-specific [FDA fact sheets](#) and [U.S. COVID-19 Vaccine Product Information](#) can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.

## COVID-19 vaccine formulations currently approved or authorized in the United States

The table below can be found [here](#).

### COVID-19 vaccine products currently approved or authorized in the United States

Pfizer-BioNTech							
Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Primary series		Dose
					Dose	Injection volume	
6 months–4 years	Monovalent (Use for 1st and 2nd Dose)*	Maroon	Maroon	Yes	Doses 1 and 2: 3 µg/0.2 mL		A booster dose for children who received a primary series of 2 doses of the vaccine (if the vaccine was administered as a primary series)
6 months–4 years	Bivalent (Use for 3rd Dose)	Maroon	Maroon	Yes	Dose 3: 3 µg/0.2 mL		
5–11 years	Monovalent	Orange	Orange	Yes	10 µg	0.2 mL	NA
5–11 years	Bivalent	Orange	Orange	Yes	NA	NA	10 µg
12 years and older	Monovalent	Gray	Gray	No	30 µg	0.3 mL	NA
12 years and older	Bivalent	Gray	Gray	No	NA	NA	30 µg
Moderna							
Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Primary series		Dose
					Dose	Injection volume	
6 months–5 years	Monovalent	Dark blue	Magenta	No	25 µg	0.25 mL	NA
6 months–5 years	Bivalent*	Dark pink	Yellow	No	NA	NA	10 µg
6–11 years	Monovalent	Dark blue	Purple	No	50 µg	0.5 mL	NA
6–11 years	Bivalent	Dark blue	Gray	No	NA	NA	25 µg
12 years and older	Monovalent	Red	Light blue	No	100 µg	0.5 mL	NA
12 years and older	Bivalent	Dark blue	Gray	No	NA	NA	50 µg

\* A monovalent Pfizer-BioNTech vaccine is used for the first and second primary doses; a bivalent Pfizer-BioNTech vaccine is used for the third primary dose.

Janssen							
Janssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations. For guidance on record review, scheduling and administration of Janssen vaccine see <a href="#">Interim Clinical Considerations for Use of COVID-19 Vaccines, Appendix A</a>							
Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Primary series		Dose
					Dose	Injection volume	
18 years and older	Monovalent	Blue	No Color	No	5×10 <sup>10</sup> viral particles	0.5 mL	5×10 <sup>10</sup> viral particles


Novavax							
Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster
					Dose	Injection volume	Dose
12 years and older	Monovalent	Royal blue	No Color	No	5 µg rS and 50 µg of Matrix-M™ adjuvant	0.5 mL	5 µg rS and 50 µg of Matrix-M™ adjuvant

† Booster doses are only indicated for recipients 18 years and age and older in limited situations, see: [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)


### COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised

For primary series vaccination, Moderna, Novavax, and Pfizer COVID-19 vaccines are recommended; only monovalent vaccines are approved or authorized for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](#)). The graphic below is available [here](#)


### COVID-19 Vaccination Schedule Infographic for People who are NOT Moderately or Severely Immunocompromised




### People ages 6 through 11 years



### People ages 12 years and older



### People ages 18 years and older who previously received Janssen primary series dose



\*For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose(s).  
† A monovalent Novavax booster dose may be used in limited situations in people ages 18 years and older who completed a primary series using any COVID-19 vaccine, and are unable or unwilling to receive an mRNA vaccine. The monovalent Novavax booster dose is administered at least 6 months after the previous booster dose(s).  
‡ Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations>

### Considerations for intervals for mRNA COVID-19 vaccine primary series

**An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12-39 years.** COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (Pfizer vaccine) or 4-week (Moderna vaccine) interval between the first and second dose. A 3- or 4-week interval continues to be the recommended interval for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about [COVID-19 community levels](#) or an individual's higher risk for severe disease).

mRNA COVID-19 vaccines are safe and effective at the FDA-approved or FDA-authorized intervals, but a longer interval may be considered for some populations. While absolute risk remains small, the risk for myocarditis is higher for males ages 12-39 years, and this risk might be reduced by extending the interval between the first and second dose. [Some studies](#) in adolescents (ages 12-17 years) and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit. **In summary, an 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12-39 years.**

## **COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised**

People with immunocompromising conditions or people who take immunosuppressive medications or therapies are [at increased risk for severe COVID-19](#). Because the immune response following COVID-19 vaccination may differ in people who are moderately or severely immunocompromised at the time of vaccination, specific guidance for this population is provided.


For primary series vaccination, Moderna, Novavax, and Pfizer COVID-19 vaccines are recommended; only monovalent vaccines are approved or authorized for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](#)).

For booster vaccination, Moderna and Pfizer are recommended. Recommendations vary based on age and primary series product.


People who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for that dose. For example, people who become moderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary doses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the booster dose. The graphic below is available [here](#).

# COVID-19 Vaccination Schedule Infographic for People who ARE Moderately or Severely Immunocompromised


## People ages 6 months through 4 years




## People age 5 years




## People ages 6 through 11 years



## People ages 12 years and older



## People ages 18 years and older who previously received Janssen primary series dose<sup>‡</sup>



\*For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

†A monovalent Novavax booster dose may be used in limited situations in people ages 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable or unwilling to receive an mRNA vaccine. The monovalent Novavax booster dose is administered at least 6 months after completion of a primary series.

‡Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a>



## VACCINE MANAGEMENT

### **Pfizer 12+ bivalent single dose vials now available for ordering by Primary Care Provider (PCP) Sites**

The Pfizer bivalent vaccine formulation for 12+ is now available in single dose vials. Due to limited quantities of this formulation, it is currently being made available only to PCP sites (pediatricians, family practices, internal medicine offices, community health centers). To add this vaccine formulation/packaging click on the "[add a vaccine](#)" button in the lower left-hand corner of the ordering screen.

See below for additional information about the SDV presentation of the Pfizer (12+) Bivalent COVID-19 Vaccine:

- The order quantity is 50 doses.
  - All single-dose vials, plan to use every single dose.
- Product dimensions: 1.47in x 1.535in x 3.504in
  - Storage space required equals that of a 300-dose MDV order
- **SDVs will not include ancillary kits.** SDVs do not require the use of low-dead-volume syringes.
- This product is new packaging, not a new vaccine. Storage and handling requirements remain the same as the Pfizer bivalent multi-dose vial. (Store at ultra-low temperature until expiry, may refrigerate up to 10 weeks within the expiry period).

### **Pfizer EUA to BLA switch - gray cap, monovalent, ages 12+**

**The EUA-labeled product is no longer available for ordering in the MIIS.**

This is due to a depletion of the product. Provider sites should now switch to the BLA-labeled product (COMIRNATY), which is interchangeable with the EUA-labeled product and available to order in MIIS.

### **Novavax COVID-19 vaccine No Longer Available to Order**

**Novavax product is no longer be available for ordering in the MIIS.**

Please note that all other COVID-19 vaccine formulations will remain available to order.

### **Vaccine Inventory Management Reminder**

Proper vaccine inventory management is critical to ensure expired or vaccines past the Beyond Use Date (BUD) are not administered to patients. Vaccine inventory should be checked daily. During the daily check (1) review and compare your physical inventory to your MIIS inventory, (2) process storage and handling issues in the MIIS for all wasted or expired doses. Vaccine orders may be canceled or reduced due to MIIS inventory showing high inventory or expired vaccines. If you do have expired or wasted vaccines, be sure to process a vaccine storage and handling problem in the MIIS before placing your next vaccine order request.

### **Watch for Expired Vaccine**

We continue to encourage you to properly manage and report your inventory:

- Practice first in/first out inventory management.
- Store older vaccines to the front of the refrigerator or freezer unit.
- Continually monitor vaccines to help reduce administration errors.
- Verify expiry dates using the manufacturers' online checkers:
  - **Pfizer:** <https://lotexpiry.cvdvaccine.com>
  - **Moderna:** <https://modernacovid19global.com/vial-lookup>
  - **Novavax:** <https://us.novavaxcovidvaccine.com/hcp>
  - **Johnson and Johnson/Janssen:** <https://vaxcheck.jnj/>

- Ensure your inventory is up to date by reporting administered doses and processing storage and handling for expired or wasted vaccine.
- Dispose of any expired or wasted vaccine.

### Expiry Date vs Beyond Use Date (BUD)

The **expiration date** is set by the manufacturer and is the date by which the vaccine should be used. The expiration date assumes that the vaccine has been stored and handled according to the manufacturer’s guidance. Expiration dates cannot change based on how vaccine is being stored or when a vial is punctured. However, on occasion, the expiration date may be updated by the manufacturer as additional stability data become available.

**Beyond Use Date (BUD)** is the date of when the vaccine can no longer be used due to a change in storage temperature, reconstitution, puncturing the vial, etc. It is recommended to place a label with the BUD and the initials of the person making the calculation whenever a vaccine vial or box is moved to a different temperature storage unit, reconstituted, or had a vial punctured resulting in a change in the BUD.

You can find BUD guidance and labels for [Moderna](#), [Novavax](#), [Janssen](#), and [Pfizer](#) from the CDC’s U.S. COVID-19 Vaccine Product Information webpage.

### Moderna Bivalent Ancillary supply kits - Adult or Pediatric

Pediatric provider sites ordering the Moderna bivalent COVID-19 vaccine booster will be sent two pediatric ancillary kits per minimum dose order by default to accommodate double the number of doses provided in each vial. Family practices and other provider types will be sent one adult ancillary kit per minimum dose order.

- If you would like ancillary supply kits different than what is described above, please specify pediatric or adult kits requested in the notes section of your vaccine order.

### COVID Vaccines Available for ordering in the MIIS

All providers enrolled Massachusetts COVID-19 Vaccine Program (MCVP) are able to place routine orders for all of the following COVID-19 vaccine formulations through the Massachusetts Immunization Information System (MIIS).

Brand	NDC	NDC Description	Minimum ordering size
-	59267-0078-04	COVID-19 (Pfizer);(PED 6m-4y) MDV10;10-pk	
-	59267-1055-04	COVID-19 (Pfizer);(PED 5-11) MDV10;10-pk	
COMIRNATY	00069-2025-10	COVID-19; MDV6; 10-pack	
-	59267-0304-02	COVID-19 (Pfizer);BIVALENT;MDV6; 10-pack	
-	59267-1404-02	COVID-19(Pfizer);BIVALENT;SDV;10pk	
-	59267-0565-02	COVID-19 (Pfizer);BIVALENT;(PED 5-11) MDV10;10pk	
-	59267-0609-02	COVID-19 (Pfizer);BIVALENT;(PED 6m-4y) MDV10; 10-pack	
-	80777-0279-99	COVID-19 (Moderna)(PED 6m-5y)MDV10;10-pack	
-	80777-0275-	COVID-19 (Moderna); (PED 6-11)MDV5; 10-pack	

	99		
-	80777-0273-99	COVID-19 (Moderna); MDV10; 10-pack	
-	80777-0282-99	COVID-19 (Moderna); BIVALENT; MDV5; 10-pack	
	80777-0283-99	COVID-19 (Moderna); BIVALENT; (PED 6m-5y) MDV2; 10-pack	
-	59676-0580-15	COVID-19 (Janssen); MDV5; 10-pack	

- Initial shipments of the Pfizer-BioNTech vaccine for children aged 6m-4 years may state “2y to <5y” or “6m to <5y” on the vial or carton labels. Please note that vials or cartons with labels that state “2y to <5y” can be used for children aged 6m through 4 years.
- Pfizer-BioNTech vaccine vial labels and cartons may also state that a vial should be discarded 6 hours after the first dilution however as stated in the EUA Fact Sheet the timeframe for use post-dilution is actually 12 hours just like orange and gray cap Pfizer vaccine formulations.

## RESOURCES & LEARNING OPPORTUNITIES

### Moderna’s COVID-19 Vaccine Medical Updates and Interactive Office Hours

**Moderna** is kicking off a new series of regional webinars with expert panelists on Monday, January 23, 2023. The first New England webinar is on February 1 at noon: [COVID-19 Bivalent Vaccines - Addressing Myths and Misconceptions: An Evidence Based Medicine Approach](#)

### Pfizer COVID-19 Vaccine Training Webinars

January 2023: Pfizer vaccine training webinars have transitioned from live events to ON DEMAND content for all healthcare providers. They can be found at <https://www.pfizermedicalinformation.com/en-us/medical-updates>

### EUA Fact Sheets

Once a new EUA Fact Sheet is issued, it must be used. Previous ones no longer contain accurate information.

- Novavax EUAs can be found on the FDA website [here](#)
- Pfizer EUAs can be found on the FDA website [here](#)
- Moderna EUAs can be found on the FDA website [here](#)
- Janssen EUAs can be found on the FDA website [here](#)

### “At a Glance” Summaries

The CDC “At a Glance” Summaries include Storage and Handling basics, Preparation and Administration Basics, and a Schedule graphic.

- Pfizer <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf>
- Moderna <https://www.cdc.gov/vaccines/covid-19/info-by->

- [product/moderna/downloads/vaccine-at-a-glance.pdf](#)
- Novavax <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-prep-admin-summary.pdf>

### Standing Orders

- Novavax <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-standing-orders.pdf>
- CDC's Moderna COVID-19 Vaccine info (including the standing orders below) <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
- Moderna 6 months through 5 years of age [https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/infant\\_standing-orders.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/infant_standing-orders.pdf)
- Moderna 6 through 11 years of age <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/6-11-standing-orders.pdf>
- Moderna 12 years of age and older <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/12-17-standing-orders.pdf>
- CDC's Pfizer COVID-19 Vaccine info (including the standing orders below) <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>
- Pfizer 6 months through 4 years of age <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/infant-standing-orders.pdf>
- Pfizer 5 through 11 years of age [https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer\\_PED\\_StandingOrders.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer_PED_StandingOrders.pdf)
- Pfizer, Monovalent and Bivalent: 12 years of age and older <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/gray-cap-Pfizer-BioNTech-standing-orders.pdf>

### Helpful Reference Materials

- [Interim COVID-19 Immunization Schedule](#)
- [Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States](#)
- [AAP's Pediatric COVID-19 Vaccine Dosing Quick Reference Guide](#)
- [Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](#)
- [Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group](#)
- [Vaccine administration errors and deviations \(Appendix D\)](#)
- [FAQs for the Interim Clinical Considerations](#)
- [COVID-19 vaccination and SARS-CoV-2 infection](#)
- [People who received COVID-19 vaccine outside the United States \(Appendix B\)](#)
- [People who received COVID-19 vaccine as part of a clinical trial \(Appendix C\)](#)

- [Triage of people with a history of allergies or allergic reactions \(Appendix E\)](#)
- [Resources to Promote COVID-19 Vaccines for Children & Teens](#) (includes social media graphics, posters, videos, external partner resources)
- [Stay Up to Date with COVID-19 Vaccines Including Boosters](#) (the COVID19 booster tool can be found here also)

#### **Information for parents and caregivers:**

- [Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC](#)
- [Frequently Asked Questions about COVID-19 Vaccination in Children | CDC](#)
- [6 Things to Know about COVID-19 Vaccination for Children | CDC](#)
- [V-safe After Vaccination Health Checker | CDC](#)
- [COVID-19 Vaccine: Frequently Asked Questions | American Academy of Pediatrics](#)

#### **COVID-19 Vaccine Training Modules**

CDC's four training modules (General Overview, Pfizer, Moderna, Janssen) can be found [here](#).

#### **COVID-19 Vaccine Webinar Series**

CDC is offering a series of brief (15-20 minute) webinars addressing topics around COVID-19 vaccination. These interactive, web-based training modules offer a real-world perspective on different issues around COVID-19 vaccines. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed. The landing page for all mini webinars is here: <https://www.cdc.gov/vaccines/covid-19/training-education/webinars.html>

#### **CDC interactive tool for the public to assess if they are eligible for a booster dose of COVID-19 vaccine**

CDC has an interactive tool to help users identify whether they (or someone else) need to receive a booster dose of COVID-19 vaccine. The "Find Out When You Can Get Your Booster" tool asks a series of simple questions about age, immunocompromise, number and type of previous doses of COVID-19 vaccines, and how long ago they received the most recent vaccination. From these answers, the tool reports whether a booster dose may be beneficial and presents considerations for when to receive it. Find the tool [here](#).

**Morbidity and Mortality Weekly Report**, better known as MMWR, is CDC's primary publication for disseminating the science it produces. The staff at MMWR have launched a [landing page](#) to help people find the latest information on COVID-19 vaccine effectiveness and safety.

#### **Recent CDC MMWRs**

January 27, 2023 (Early Release)

- [Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages — United States, January 2023](#)

January 27, 2023

- [Laboratory-Confirmed COVID-19 Case Incidence Rates Among Residents in Nursing Homes by Up-to-Date Vaccination Status — United States, October 10, 2022–January 8, 2023](#)
- [SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine — Ohio and Rhode Island, September–November 2022](#)

January 25, 2023 (Early Release)

- [Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023](#)
- [Spike Gene Target Amplification in a Diagnostic Assay as a Marker for Public Health Monitoring of Emerging SARS-CoV-2 Variants — United States, November 2021–January 2023](#)

January 20, 2023

- [Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022](#)

January 13, 2023

- [Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023](#)

## **MDPH RESOURCES**

### **Massachusetts Resources**

- [COVID-19 Vaccine main page](#)
- COVID-19 vaccinations for [children ages 6 months to 4 years old](#)
- COVID-19 vaccinations for [children ages 5-17](#)
- Search for a COVID-19 vaccine at [vaxfinder.mass.gov](https://vaxfinder.mass.gov)
- COVID-19 [booster frequently asked questions](#)
- COVID-19 Vaccine Resource Line/2-1-1 is available for individuals who are unable to use Vaxfinder, or have difficulty accessing the internet. Available in English and Spanish and has translators available in approximately 100 additional languages.
- COVID-19 Vaccine Training and Education Resources for Providers: <https://www.mass.gov/info-details/covid-19-vaccine-training-and-education-resources-for-providers>
- [Multilingual COVID-19 Materials](#). Resources related to Coronavirus Disease 2019 (COVID-19) in multiple languages. Includes videos and printables on topics like vaccine safety, pregnancy and the vaccine, and FAQs.

### **Immunization Division Main Number**

For questions about immunization recommendations, disease reporting, etc.

Phone: 617-983-6800 (24/7 MDPH Epi line)

Fax: 617-983-6840

Website: <https://www.mass.gov/topics/immunization>

**MIIS Help Desk**

Phone: 617-983-4335

Fax: 857-323-8321

Email questions to: [miishelpdesk@mass.gov](mailto:miishelpdesk@mass.gov)

Website: <https://www.mass.gov/massachusetts-immunization-information-system-miis>

**MDPH Vaccine Unit**

Phone: 617-983-6828

Email questions to: [dph-vaccine-management@mass.gov](mailto:dph-vaccine-management@mass.gov)

Website: <https://www.mass.gov/service-details/vaccine-management>

**Color Help**

Email questions to: [colorhelp@mass.gov](mailto:colorhelp@mass.gov)

Website: <https://www.mass.gov/info-details/vaccine-clinic-management-platform>

**COVID-19 Email Box**

Email questions to: [COVID-19-Vaccine-Plan-MA@mass.gov](mailto:COVID-19-Vaccine-Plan-MA@mass.gov)